stockportfolio.pro
ALC vs BIIB: Which Stock Is the Better Buy?
Alcon Inc. and Biogen Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ALC vs BIIB, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Alcon Inc. (ALC) | Biogen Inc. (BIIB) | |
|---|---|---|
| Market cap | $32.2B | $31.9B |
| Revenue (latest FY) | $10.40B | $9.89B |
| Net income (latest FY) | $980.00M | $1.29B |
| Revenue growth (5y CAGR) | 6.1% | -6.0% |
| Net margin | 9.4% | 13.1% |
| Return on equity | 4.5% | 7.1% |
| P/E ratio | 39.6 | 23.3 |
| Dividend yield | 0.5% | — |
| Profitable years (of last 10) | 4 | 10 |
| Positive free cash flow | Yes | Yes |
See the full ALC vs BIIB breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ALC's full financials → Open BIIB's full financials →More comparisons
Frequently asked questions
Which is bigger, ALC or BIIB?
Alcon Inc. is larger by market capitalization — $32.2B versus $31.9B.
Which grows faster, ALC or BIIB?
Over the last five fiscal years, Alcon Inc. grew revenue faster — 6.1%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.